These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 12534414

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
    Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J.
    Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
    [Abstract] [Full Text] [Related]

  • 3. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
    Bardhan KD, Bodemar G, Geldof H, Schütz E, Heath A, Mills JG, Jacques LA.
    Aliment Pharmacol Ther; 2000 Jan; 14(1):23-34. PubMed ID: 10632642
    [Abstract] [Full Text] [Related]

  • 4. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
    Thumshirn M, Coulie B, Camilleri M, Zinsmeister AR, Burton DD, Van Dyke C.
    Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
    Clemens CH, Samsom M, Van Berge Henegouwen GP, Fabri M, Smout AJ.
    Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM.
    Arch Intern Med; 2001 Jul 23; 161(14):1733-40. PubMed ID: 11485506
    [Abstract] [Full Text] [Related]

  • 11. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
    Maxton DG, Morris J, Whorwell PJ.
    Aliment Pharmacol Ther; 1996 Aug 23; 10(4):595-9. PubMed ID: 8853764
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome.
    Simrén M, Abrahamsson H, Björnsson ES.
    Gut; 2001 Jan 23; 48(1):20-7. PubMed ID: 11115818
    [Abstract] [Full Text] [Related]

  • 16. Review article: clinical pharmacology of alosetron.
    Gunput MD.
    Aliment Pharmacol Ther; 1999 May 23; 13 Suppl 2():70-6. PubMed ID: 10429744
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
    Watson ME, Lacey L, Kong S, Northcutt AR, McSorley D, Hahn B, Mangel AW.
    Am J Gastroenterol; 2001 Feb 23; 96(2):455-9. PubMed ID: 11232690
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
    Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, Carter E, Lotronex Investigator Team.
    Am J Gastroenterol; 2001 Sep 23; 96(9):2662-70. PubMed ID: 11569692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.